TrialBlood advances2024

Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.

Abdulraheem Yacoub et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.